Literature DB >> 18543046

Prognosis of resected ampullary adenocarcinoma by preoperative serum CA19-9 levels and platelet-lymphocyte ratio.

Richard A Smith1, Paula Ghaneh, Robert Sutton, Michael Raraty, Fiona Campbell, John P Neoptolemos.   

Abstract

BACKGROUND: The objective of this study was to evaluate whether preoperative CA19-9 levels and the platelet-lymphocyte ratio (PLR) might reflect prognostic indices for resected ampullary adenocarcinoma.
MATERIALS AND METHODS: Data were collected prospectively over a 10-year period for consecutive patients undergoing pancreatoduodenectomy for malignancy.
RESULTS: Both preoperative PLR and CA19-9 results were available in 52 cases of resected ampullary adenocarcinoma. Preoperative CA19-9 levels of </=150 kU/l (or </=300 kU/l in the presence of bilirubin levels >35 micromol/l) and a PLR of </=160 were found to represent the optimal cut-off values to risk stratify patients. If both levels were elevated (n = 8), patients had a median overall survival of 10.1 months. If either CA19-9 or PLR were elevated individually (n = 23), patients had a median survival of 25.2 months. For cases where both levels were less than the cut-off values (n = 21), the median overall survival time was not reached but was greater than 60 months (log rank, p < 0.001). This preoperative risk stratification was found to remain a significant independent predictor of survival on multivariate analysis (Cox, p = 0.001) alongside resection margin status (p = 0.002) and tumor size (p = 0.051).
CONCLUSIONS: Preoperative CA19-9 and PLR both merit further evaluation as prognostic indices in resected ampullary adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18543046     DOI: 10.1007/s11605-008-0554-3

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  41 in total

1.  Platelet count and survival in patients with colorectal cancer--a preliminary study.

Authors:  M Monreal; J Fernandez-Llamazares; M Piñol; J F Julian; M Broggi; D Escola; A Abad
Journal:  Thromb Haemost       Date:  1998-05       Impact factor: 5.249

2.  Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.

Authors:  J H Klinkenbijl; J Jeekel; T Sahmoud; R van Pel; M L Couvreur; C H Veenhof; J P Arnaud; D G Gonzalez; L T de Wit; A Hennipman; J Wils
Journal:  Ann Surg       Date:  1999-12       Impact factor: 12.969

Review 3.  Dangers of using "optimal" cutpoints in the evaluation of prognostic factors.

Authors:  D G Altman; B Lausen; W Sauerbrei; M Schumacher
Journal:  J Natl Cancer Inst       Date:  1994-06-01       Impact factor: 13.506

4.  Prognostic value of CA 19-9 serum course in pancreatic cancer.

Authors:  F Safi; W Schlosser; S Falkenreck; H G Beger
Journal:  Hepatogastroenterology       Date:  1998 Jan-Feb

5.  Effect of preoperative biliary stenting on immediate outcome after pancreaticoduodenectomy.

Authors:  P Jagannath; V Dhir; S Shrikhande; R C Shah; P Mullerpatan; K M Mohandas
Journal:  Br J Surg       Date:  2005-03       Impact factor: 6.939

6.  Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up.

Authors:  Taylor S Riall; John L Cameron; Keith D Lillemoe; Jordan M Winter; Kurtis A Campbell; Ralph H Hruban; David Chang; Charles J Yeo
Journal:  Surgery       Date:  2006-08-28       Impact factor: 3.982

Review 7.  Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer.

Authors:  K S Goonetilleke; A K Siriwardena
Journal:  Eur J Surg Oncol       Date:  2006-11-09       Impact factor: 4.424

8.  Adjuvant chemo-radiotherapy in ampullary cancers.

Authors:  S S Sikora; P Balachandran; K Dimri; N Rastogi; A Kumar; R Saxena; V K Kapoor
Journal:  Eur J Surg Oncol       Date:  2005-03       Impact factor: 4.424

9.  Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater.

Authors:  Sunil Krishnan; Vishal Rana; Douglas B Evans; Gauri Varadhachary; Prajnan Das; Sumita Bhatia; Marc E Delclos; Nora A Janjan; Robert A Wolff; Christopher H Crane; Peter W Pisters
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-05       Impact factor: 7.038

10.  Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas.

Authors:  R C Montgomery; J P Hoffman; L B Riley; A Rogatko; J A Ridge; B L Eisenberg
Journal:  Ann Surg Oncol       Date:  1997 Oct-Nov       Impact factor: 5.344

View more
  41 in total

Review 1.  Cholangiocarcinoma in primary sclerosing cholangitis.

Authors:  Ghulam Abbas; Keith D Lindor
Journal:  J Gastrointest Cancer       Date:  2009-08-25

2.  The effect of peripheral blood values on prognosis of patients with locally advanced gastric cancer before treatment.

Authors:  Mehmet Aliustaoglu; Ahmet Bilici; Bala Basak Oven Ustaalioglu; Volkan Konya; Murat Gucun; Mesut Seker; Mahmut Gumus
Journal:  Med Oncol       Date:  2009-10-22       Impact factor: 3.064

3.  Pretreatment platelet-to-lymphocyte ratio (PLR) as a predictor of response to first-line platinum-based chemotherapy and prognosis for patients with non-small cell lung cancer.

Authors:  Hongbing Liu; Ying Wu; Zhaofeng Wang; Yanwen Yao; Fangfang Chen; He Zhang; Yunfen Wang; Yong Song
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

4.  Preoperative neutrophil-to-lymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma.

Authors:  G Garcea; N Ladwa; C P Neal; M S Metcalfe; A R Dennison; D P Berry
Journal:  World J Surg       Date:  2011-04       Impact factor: 3.352

5.  Prognostic value of carbohydrate tumor markers and inflammation-based markers in metastatic or recurrent gastric cancer.

Authors:  Qing Wang; Yang Yang; Ya-Ping Zhang; Zhengyun Zou; Xiaoping Qian; Baorui Liu; Jia Wei
Journal:  Med Oncol       Date:  2014-10-26       Impact factor: 3.064

6.  The basal nutritional state of PDAC patients is the dominant factor for completing adjuvant chemotherapy.

Authors:  Daisaku Yamada; Hidetoshi Eguchi; Tadafumi Asaoka; Hideo Tomihara; Takehiro Noda; Hiroshi Wada; Koichi Kawamoto; Kunihito Gotoh; Yutaka Takeda; Masahiro Tanemura; Masaki Mori; Yuichiro Doki
Journal:  Surg Today       Date:  2017-04-18       Impact factor: 2.549

7.  Preoperative platelet/lymphocyte ratio is a superior prognostic factor compared to other systemic inflammatory response markers in ovarian cancer patients.

Authors:  Wei-wei Zhang; Ke-jun Liu; Guo-lin Hu; Wei-jiang Liang
Journal:  Tumour Biol       Date:  2015-06-11

8.  Resection for hilar cholangiocarcinoma: analysis of prognostic factors and the impact of systemic inflammation on long-term outcome.

Authors:  Traian Dumitrascu; Dragos Chirita; Mihnea Ionescu; Irinel Popescu
Journal:  J Gastrointest Surg       Date:  2013-01-15       Impact factor: 3.452

9.  Neutrophil-to-Lymphocyte Ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as Possible Prognostic Markers for Patients Undergoing Resection of Adrenocortical Carcinoma.

Authors:  Mechteld C de Jong; Radu Mihai; Shahab Khan
Journal:  World J Surg       Date:  2020-11-21       Impact factor: 3.352

10.  Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients.

Authors:  Basem Azab; Neeraj Shah; Jared Radbel; Pamela Tan; Vijaya Bhatt; Steven Vonfrolio; Ayman Habeshy; Antonio Picon; Scott Bloom
Journal:  Med Oncol       Date:  2013-01-03       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.